Citigroup
HRTX icon

Citigroup’s Heron Therapeutics HRTX Stock Holding History

Citigroup’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-8,400
Closed -$99K – 7595
2020
Q1 		$99K Sell
8,400
-2,500
-23% -$47K ﹤0.01% 5348
2019
Q4 		$256K Buy
10,900
+4,900
+82% +$108K ﹤0.01% 4977
2019
Q3 		$111K Sell
6,000
-15,800
-72% -$291K ﹤0.01% 5599
2019
Q2 		$405K Sell
21,800
-3,300
-13% -$65.9K ﹤0.01% 4627
2019
Q1 		$613K Buy
25,100
+19,400
+340% +$508K ﹤0.01% 3963
2018
Q4 		$148K Sell
5,700
-2,300
-29% -$63.2K ﹤0.01% 5312
2018
Q3 		$253K Sell
8,000
-2,400
-23% -$89.4K ﹤0.01% 4998
2018
Q2 		$404K Sell
10,400
-8,500
-45% -$271K ﹤0.01% 4336
2018
Q1 		$522K Buy
18,900
+7,600
+67% +$172K ﹤0.01% 3948
2017
Q4 		$205K Buy
11,300
+3,700
+49% +$60.3K ﹤0.01% 5015
2017
Q3 		$123K Buy
7,600
+6,700
+744% +$105K ﹤0.01% 5399
2017
Q2 		$12K Sell
900
-2,500
-74% -$36.2K ﹤0.01% 6459
2017
Q1 		$51K Sell
3,400
-3,200
-48% -$44.3K ﹤0.01% 5683
2016
Q4 		$86K Sell
6,600
-3,900
-37% -$61.2K ﹤0.01% 5863
2016
Q3 		$181K Sell
10,500
-4,600
-30% -$85.3K ﹤0.01% 4734
2016
Q2 		$273K Buy
15,100
+11,100
+278% +$217K ﹤0.01% 4214
2016
Q1 		$76K Sell
4,000
-500
-11% -$9.87K ﹤0.01% 5861
2015
Q4 		$120K Sell
4,500
-107,900
-96% -$2.89M ﹤0.01% 5223
2015
Q3 		$2.74M Buy
+112,400
New +$3.75M ﹤0.01% 2183

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Citigroup's HRTX Position: Q1 2026 in Review

Citigroup increased its Heron Therapeutics (HRTX) stake by 108% in Q1 2026, buying an estimated $4.36K and bringing the position to 7,240 shares worth $5.79K. The position accounts for ﹤0.01% of the portfolio, ranked #5223.

Citigroup first reported a position in HRTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $14.9M in Q2 2017. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Citigroup held 7,240 shares of Heron Therapeutics worth $5.79K as of Q1 2026.
  • Citigroup bought 3,762 Heron Therapeutics shares in Q1 2026, an estimated $4.36K.
  • Heron Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5223 holding.
  • Citigroup first reported a position in Heron Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Citigroup's Heron Therapeutics position peaked at $14.9M in Q2 2017.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.